Sanofi $SNY
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS100
PHASE 3 / 2-356
RECRUITING42
READOUTS ≤12 MONTHS33
READOUT SLIPPED >6 MO37%
Delay Index: of 76 active trials registered more than a year ago, 28 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Sanofi on the live radar map → 📅 $SNY readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SAR441344 IV NCT04879628 |
P2 | Active, not recruiting | Multiple Sclerosis | 129 | 2022-09-21 (-3 mo) |
| LUMINA 2 NCT05002777 |
P2 | Active, not recruiting | Warm Autoimmune Hemolytic Anemia (wAIHA) | 22 | 2024-05-23 (+10 mo) |
| IRAKLIA NCT05405166 |
P3 | Active, not recruiting | Plasma Cell Myeloma Recurrent | 531 | 2024-11-06 (+5 mo) |
| LEAP2MONO NCT05222906 |
P3 | Active, not recruiting | Gaucher's Disease Type III | 43 | 2025-10-02 (+13 mo) |
| BIVV020 (SAR445088) NCT05156710 |
P2 | Active, not recruiting | Transplant Rejection | 48 | 2025-10-21 (+11 mo) |
| PERIDOT NCT05206773 |
P3 | Active, not recruiting | Fabry Disease | 122 | 2025-12-17 (+13 mo) |
| IZALCO NCT05704049 |
P2 | Active, not recruiting | Relapsed/Refractory Multiple Myeloma | 118 | 2025-12-22 (+18 mo) |
| RESOLUTE NCT05588843 |
P2 | Active, not recruiting | Colitis Ulcerative | 187 | 2026-02-10 (+8 mo) |
| Baby-COMET NCT04910776 |
P3 | Active, not recruiting | Glycogen Storage Disease Type II | 17 | 2026-03-02 (+22 mo) |
| Dupilumab NCT05731128 |
P2 | Active, not recruiting | Colitis Ulcerative | 68 | 2026-05-13 (+23 mo) |
| CARAT NCT05280548 |
P3 | Active, not recruiting | Fabry Disease | 104 | 2026-05-22 (+17 mo) |
| MOBILIZE NCT06290128 |
P3 | Active, not recruiting | Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Polyneuropathy, Inflammatory Demyelinating, Chronic | 109 | 2026-06-10 (+4 mo) |
| ESTUARY NCT06407934 |
P3 | Active, not recruiting | Dermatitis Atopic | 1541 | 2026-06-10 |
| Amlitelimab NCT06557772 |
P2 | Active, not recruiting | Coeliac Disease; Celiac Disease | 229 | 2026-08-05 |
| APATURA NCT05039840 |
P2 | Active, not recruiting | Systemic Lupus Erythematosus | 109 | 2026-09-04 (+39 mo) |
| CEREN-1 NCT06834347 |
P3 | Active, not recruiting | Chronic Rhinosinusitis With Nasal Polyps | 231 | 2026-09-23 (-4 mo) |
| CEREN-2 NCT06834360 |
P3 | Active, not recruiting | Chronic Rhinosinusitis With Nasal Polyps | 216 | 2026-09-24 (-3 mo) |
| rilzabrutinib NCT07216079 |
P3 | Active, not recruiting | Immune Thrombocytopenia | 3 | 2026-11-25 |
| Yellow fever vaccine (live) NCT07103148 |
P3 | Active, not recruiting | Yellow Fever Immunization | 2440 | 2026-11-28 (+4 mo) |
| Pandemic flu H5 HA mRNA SD2 vaccine NCT06907511 |
P1/2 | Active, not recruiting | Pandemic Influenza Immunization; Healthy Volunteers | 720 | 2026-12-01 (+6 mo) |
| CHROMA CD NCT06958536 |
P2 | Recruiting | Crohn's Disease | 99 | 2026-12-17 |
| COLOR UC NCT06975722 |
P2 | Active, not recruiting | Ulcerative Colitis | 105 | 2026-12-17 |
| RESULT NCT06500702 |
P2 | Recruiting | Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion | 84 | 2026-12-23 |
| PCV21 NCT07247188 |
P3 | Recruiting | Sickle Cell Disease | 100 | 2027-01-07 |
| SAR445877 NCT05584670 |
P1/2 | Recruiting | Solid Tumor | 542 | 2027-01-19 (-5 mo) |
| BRIGHTEN NCT07170917 |
P2 | Recruiting | Hidradenitis Suppurativa | 208 | 2027-02-09 (-6 mo) |
| Rilzabrutinib dose 1 NCT06984627 |
P2 | Recruiting | Graves' Disease | 30 | 2027-02-11 (+6 mo) |
| CEREN-3 NCT07424144 |
P3 | Active, not recruiting | Chronic Rhinosinusitis With Nasal Polyps | 59 | 2027-02-17 |
| ATLAS-NEO NCT05662319 |
P3 | Active, not recruiting | Hemophilia | 91 | 2027-03-25 (+11 mo) |
| SubQSA NCT06356571 |
P2 | Active, not recruiting | Plasma Cell Myeloma Refractory | 64 | 2027-04-01 (+3 mo) |
| IMROZ NCT03319667 |
P3 | Active, not recruiting | Plasma Cell Myeloma | 475 | 2027-04-05 (+52 mo) |
| SAR444336 NCT07156175 |
P2 | Active, not recruiting | Microscopic Colitis | 60 | 2027-04-08 |
| FABULINUS NCT06111586 |
P2 | Active, not recruiting | Type 1 Diabetes Mellitus | 197 | 2027-04-28 |
| T1D OBTAIN NCT06812988 |
P2 | Active, not recruiting | Type 1 Diabetes Mellitus | 84 | 2027-04-29 (-3 mo) |
| FREXALT NCT06141473 |
P3 | Active, not recruiting | Multiple Sclerosis | 1655 | 2027-05-06 |
| SAR402663 NCT06660667 |
P1/2 | Active, not recruiting | Neovascular Age-related Macular Degeneration | 66 | 2027-05-18 |
| Dupilumab NCT05263206 |
P3 | Recruiting | Pruritus | 284 | 2027-06-02 (+26 mo) |
| PCV21 vaccine NCT07348692 |
P3 | Recruiting | Pneumococcal Immunization; Healthy Volunteers | 2195 | 2027-06-07 |
| AIRLYMPUS NCT06676319 |
P2 | Active, not recruiting | Asthma | 556 | 2027-06-21 (-4 mo) |
| VITALIZE NCT06290141 |
P3 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy | 160 | 2027-07-09 (+20 mo) |
| Frexcite NCT07325292 |
P3 | Recruiting | Multiple Sclerosis | 160 | 2027-07-15 |
| LIBRA NCT06975865 |
P3 | Recruiting | Sickle Cell Disease | 192 | 2027-07-23 |
| PCV21 vaccine NCT06975878 |
P3 | Active, not recruiting | Pneumococcal Immunization; Healthy Volunteers | 1092 | 2027-08-25 |
| PCV21 vaccine NCT06824181 |
P3 | Active, not recruiting | Pneumococcal Immunization | 580 | 2027-09-10 (+4 mo) |
| Isatuximab NCT04643002 |
P1/2 | Recruiting | Plasma Cell Myeloma Refractory | 258 | 2027-09-13 (+53 mo) |
| CLAROS NCT07225569 |
P2 | Recruiting | Hidradenitis Suppurativa | 144 | 2027-09-22 |
| AQUA NCT06241118 |
P3 | Active, not recruiting | Dermatitis Atopic | 464 | 2027-09-30 (+18 mo) |
| SAR446597 NCT07215234 |
P1/2 | Recruiting | Geographic Atrophy | 104 | 2027-10-13 |
| PCV21 vaccine NCT06824194 |
P3 | Active, not recruiting | Pneumococcal Immunization | 2360 | 2027-10-22 (+5 mo) |
| Dupilumab NCT06293053 |
P3 | Recruiting | Prurigo Nodularis | 18 | 2027-10-28 |
| LUNA 4 NCT07007962 |
P3 | Recruiting | Immune Thrombocytopenia | 60 | 2027-11-05 |
| IIV-HD (standalone) NCT07890454 |
P3 | Recruiting | Immunization; Healthy Volunteers | 6000 | 2027-12-28 |
| Flu H5 egg pandemic low dose vaccine, with adjuvant NCT07779408 |
P1/2 | Recruiting | Healthy Volunteers; Influenza | 640 | 2028-02-22 |
| SKYPS NCT02991469 |
P2 | Recruiting | Juvenile Idiopathic Arthritis | 51 | 2028-03-01 (+119 mo) |
| KIBOU-T1D NCT06791291 |
P2 | Active, not recruiting | Type 1 Diabetes Mellitus | 5 | 2028-03-06 |
| MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA) NCT07710872 |
P3 | Recruiting | Meningococcal Infection; Healthy Volunteers | 4568 | 2028-03-13 |
| FREVIVA NCT06141486 |
P3 | Active, not recruiting | Multiple Sclerosis | 943 | 2028-03-24 (+15 mo) |
| DTaP-IPV-HB-PRP~T combined vaccine NCT07941622 |
P3 | Not yet recruiting | Haemophilus Influenzae Type b Immunisation; Hepatitis B Immunisation | 720 | 2028-04-27 |
| EXTENSA NCT07919899 |
P3 | Not yet recruiting | Dermatitis Atopic | 150 | 2028-05-02 |
| RSV+HMPV vaccine NCT07734649 |
P1/2 | Recruiting | Respiratory Syncytial Virus Immunization; Human Metapneumovirus Immunization | 2400 | 2028-05-03 |
| SUNSCAPE-1 NCT07184996 |
P3 | Recruiting | Ulcerative Colitis | 980 | 2028-05-09 |
| LUMINA 3 NCT07086976 |
P3 | Recruiting | Autoimmune Haemolytic Anaemia | 90 | 2028-05-31 |
| βETA PRESERVE NCT07088068 |
P3 | Recruiting | Type 1 Diabetes Mellitus | 723 | 2028-06-06 |
| AURALIGHT NCT07812116 |
P2 | Recruiting | Hidradenitis | 156 | 2028-06-16 |
| RILIEF NCT07190196 |
P3 | Recruiting | Immunoglobulin G4 Related Disease | 124 | 2028-06-28 |
| ELEVAATE OLE NCT05897424 |
P2 | Active, not recruiting | Alpha 1-Antitrypsin Deficiency; Emphysema | 185 | 2028-06-30 (+10 mo) |
| Bivalent RSV+HMPV protein vaccine NCT07810010 |
P2 | Recruiting | Respiratory Syncytial Virus; Human Metapneumovirus | 8000 | 2028-07-03 |
| Acne mRNA (messenger ribonucleic acid) vaccine NCT07756957 |
P2 | Not yet recruiting | Acne | 410 | 2028-07-19 |
| SAR445877 NCT07692204 |
P2 | Recruiting | Gastric Cancer; Oesophageal Carcinoma | 30 | 2028-08-02 |
| SUNSCAPE-2 NCT07185009 |
P3 | Recruiting | Ulcerative Colitis | 751 | 2028-09-21 |
| schoolROCK NCT07116031 |
P2 | Recruiting | Chronic Graft Versus Host Disease | 37 | 2028-09-25 (-29 mo) |
| ROCKnrol-1 NCT06143891 |
P3 | Active, not recruiting | Chronic Graft Versus Host Disease | 260 | 2028-09-29 |
| OPALS NCT07704580 |
P1/2 | Recruiting | Rheumatoid Arthritis | 140 | 2028-10-26 |
| Isatuximab intravenous (IV) NCT05669989 |
P2 | Enrolling by invitation | Plasma Cell Myeloma | 70 | 2028-11-30 (+29 mo) |
| Dupilumab NCT06191315 |
P3 | Enrolling by invitation | Wheezing; Asthma | 90 | 2028-12-21 |
| RIVER-AD NCT05492578 |
P2/3 | Active, not recruiting | Dermatitis Atopic | 1856 | 2029-01-22 (+38 mo) |
| ROCKaspire NCT06082037 |
P3 | Recruiting | Lung Transplant Rejection | 180 | 2029-01-29 (+28 mo) |
| ENSEMBLE NCT06914908 |
P2 | Active, not recruiting | Chronic Rhinosinusitis With Nasal Polyps | 71 | 2029-02-22 (-23 mo) |
| BrAAVe NCT06844214 |
P1/2 | Recruiting | Myotonic Dystrophy | 32 | 2029-02-28 |
| Tolebrutinib NCT06372145 |
P3 | Active, not recruiting | Relapsing Multiple Sclerosis; Secondary Progressive Multiple Sclerosis | 2500 | 2029-04-30 |
| STARSCAPE-1 NCT07184931 |
P3 | Recruiting | Crohn's Disease | 980 | 2029-05-14 |
| ZIRCON NCT07286214 |
P3 | Recruiting | Polymyalgia Rheumatica | 300 | 2029-06-04 |
| TREMHANCE NCT07688213 |
P2 | Recruiting | Dementia, Alzheimer's Type; Alzheimer's Disease | 160 | 2029-07-31 |
| ATLAS-KIDS NCT07285460 |
P3 | Recruiting | Hemophilia | 85 | 2029-08-04 |
| STARSCAPE-2 NCT07184944 |
P3 | Recruiting | Crohn's Disease | 751 | 2029-08-13 |
| FREXERA NCT07412470 |
P2/3 | Recruiting | Kidney Transplant Rejection | 526 | 2029-08-15 |
| Belumosudil NCT07771439 |
P3 | Recruiting | Chronic Graft Versus Host Disease | 356 | 2029-09-14 |
| LTS NCT06859099 |
P3 | Enrolling by invitation | Polyneuropathy, Inflammatory Demyelinating, Chronic | 300 | 2029-10-03 |
| THESEUS NCT07190222 |
P3 | Recruiting | Chronic Obstructive Pulmonary Disease | 942 | 2029-11-27 |
| PERSEPHONE NCT07190209 |
P3 | Recruiting | Chronic Obstructive Pulmonary Disease | 942 | 2029-11-27 |
| LEAP2KIDS NCT07927140 |
P3 | Not yet recruiting | Gaucher's Disease Type III | 18 | 2030-01-14 |
| SAR444836 NCT05972629 |
P1/2 | Active, not recruiting | Phenylketonuria | 32 | 2030-04-02 (+33 mo) |
| Isatuximab SAR650984 NCT04270409 |
P3 | Active, not recruiting | Plasma Cell Myeloma | 337 | 2030-10-14 (+34 mo) |
| AIRPHRODITE NCT06609239 |
P2 | Enrolling by invitation | Asthma | 900 | 2031-01-20 |
| Frexalimab NCT07930624 |
P3 | Not yet recruiting | Multiple Sclerosis | 2500 | 2031-05-16 |
| ATLANTIS NCT05769777 |
P2 | Active, not recruiting | Dermatitis Atopic | 999 | 2031-06-11 (+43 mo) |
| Blood draw for the laboratory assessment NCT02065011 |
P2 | Active, not recruiting | Usher's Syndrome | 9 | 2031-06-13 (+13 mo) |
| COLOSSUS NCT07793409 |
P3 | Enrolling by invitation | Chronic Obstructive Pulmonary Disease | 1508 | 2031-07-23 |
| Long term follow up in all patients who received SAR422459 in previous study TDU13583 NCT01736592 |
P2 | Active, not recruiting | Stargardt's Disease | 27 | 2033-08-29 (+58 mo) |
| rilzabrutinib NCT07923305 |
P2/3 | Not yet recruiting | Immunodeficiency Common Variable | 96 | 2035-05-10 |